Stock listing
Lang & Schwarz:A2PCBS Gossamer Bio, Inc. Aktie
German listing (Lang & Schwarz) of Gossamer Bio, Inc. · home listing NASDAQ:GOSS
Follow Gossamer Bio, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:GOSS
$10.72 USD -0.71 (-6.2%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:GOSS
- Day range
- $10.65 – $11.60 USDNov 20, 2026
- Volume
- 191,427 sharesNov 20, 2026
- Market cap
- $65.57M USDAt the close on Nov 20, 2026 · price × 6.12M shares outstanding
- 52-week range
- $8.30 – $309.60 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.13M USDMedian day 195,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:GOSS · Home | $10.72 USD | -0.71 (-6.2%) | 191,427 | $11.02 | $11.60 | $10.65 | $11.43 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GOSS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $10.72 | -0.71 | -6.2% | $11.02 | $11.60 | $10.65 | 191,427 | |
| $11.43 | +0.39 | +3.5% | $11.00 | $11.58 | $10.95 | 242,628 | |
| $11.04 | +0.06 | +0.5% | $10.85 | $11.45 | $10.22 | 221,747 | |
| $10.98 | +0.01 | +0.1% | $10.88 | $11.40 | $10.76 | 207,137 | |
| $10.97 | -0.27 | -2.4% | $11.19 | $11.40 | $10.60 | 124,138 | |
| $11.24 | -0.45 | -3.8% | $11.27 | $12.15 | $10.60 | 188,954 | |
| $11.69 | +0.41 | +3.6% | $9.76 | $11.94 | $9.71 | 335,914 | |
| $11.28 | +0.635 | +6.0% | $10.52 | $11.54 | $10.42 | 100,202 | |
| $10.65 | +0.875 | +9.0% | $10.02 | $11.58 | $9.545 | 234,614 | |
| $9.77 | +0.35 | +3.7% | $9.27 | $9.99 | $9.27 | 82,378 | |
| $9.42 | -0.53 | -5.3% | $9.77 | $9.77 | $8.91 | 151,661 | |
| $9.95 | +0.67 | +7.2% | $9.42 | $10.04 | $9.42 | 115,809 | |
| $9.28 | -0.17 | -1.8% | $9.38 | $9.68 | $8.80 | 139,401 | |
| $9.45 | -0.93 | -9.0% | $10.30 | $10.35 | $9.30 | 190,762 | |
| $10.38 | -0.31 | -2.9% | $10.56 | $10.74 | $10.19 | 179,363 | |
| $10.69 | 0.00 | 0.0% | $10.70 | $11.08 | $10.48 | 105,481 | |
| $10.69 | +0.92 | +9.4% | $9.61 | $10.88 | $9.45 | 185,734 | |
| $9.77 | +0.62 | +6.8% | $9.17 | $9.87 | $9.10 | 137,818 | |
| $9.15 | -0.455 | -4.7% | $9.61 | $9.61 | $8.72 | 250,631 | |
| $9.605 | +0.145 | +1.5% | $9.40 | $9.72 | $9.00 | 144,773 | |
| $9.46 | -0.33 | -3.4% | $9.73 | $9.957 | $9.34 | 190,522 | |
| $9.79 | +0.21 | +2.2% | $9.50 | $10.35 | $9.50 | 218,879 | |
| $9.58 | +1.15 | +13.6% | $8.41 | $9.58 | $8.30 | 212,054 | |
| $8.43 | -0.34 | -3.9% | $8.80 | $8.80 | $8.311 | 179,473 | |
| $8.77 | -0.12 | -1.3% | $8.88 | $8.995 | $8.51 | 171,100 | |
| $8.89 | -0.015 | -0.2% | $8.86 | $9.18 | $8.73 | 197,700 | |
| $8.905 | -0.855 | -8.8% | $9.59 | $9.641 | $8.77 | 360,800 | |
| $9.76 | +0.48 | +5.2% | $9.83 | $10.03 | $9.26 | 478,000 | |
| $9.28 | -0.03 | -0.3% | $9.54 | $9.54 | $8.99 | 155,000 | |
| $9.31 | -0.57 | -5.8% | $9.93 | $10.10 | $9.20 | 289,900 | |
| $9.88 | -0.30 | -2.9% | $10.02 | $10.28 | $9.657 | 196,800 | |
| $10.18 | -0.60 | -5.6% | $10.38 | $10.66 | $9.774 | 280,600 | |
| $10.78 | +0.13 | +1.2% | $10.77 | $10.93 | $10.50 | 196,600 | |
| $10.65 | -0.06 | -0.6% | $10.70 | $10.99 | $10.00 | 390,900 | |
| $10.71 | -0.22 | -2.0% | $11.19 | $11.19 | $10.19 | 235,000 | |
| $10.93 | -0.92 | -7.8% | $11.63 | $12.14 | $10.80 | 351,800 | |
| $11.85 | +0.27 | +2.3% | $11.53 | $12.46 | $11.16 | 381,900 | |
| $11.58 | +0.06 | +0.5% | $11.68 | $11.85 | $11.21 | 384,000 | |
| $11.52 | +0.58 | +5.3% | $10.46 | $11.85 | $10.33 | 516,400 | |
| $10.94 | +0.01 | +0.1% | $10.93 | $11.01 | $10.22 | 426,600 | |
| $10.93 | -0.06 | -0.5% | $10.76 | $11.68 | $10.75 | 236,100 | |
| $10.99 | -0.70 | -6.0% | $11.69 | $11.97 | $10.03 | 453,800 | |
| $11.69 | +0.41 | +3.6% | $11.48 | $12.31 | $11.35 | 195,600 | |
| $11.28 | +0.55 | +5.1% | $11.60 | $11.94 | $10.91 | 258,800 | |
| $10.73 | -1.21 | -10.1% | $12.00 | $12.49 | $10.67 | 530,100 | |
| $11.94 | +0.98 | +8.9% | $11.78 | $12.45 | $11.28 | 267,700 | |
| $10.96 | +0.58 | +5.6% | $10.77 | $11.24 | $9.961 | 271,200 | |
| $10.38 | -0.32 | -3.0% | $10.61 | $10.97 | $10.12 | 220,300 | |
| $10.70 | -0.03 | -0.3% | $10.95 | $11.08 | $10.07 | 325,900 | |
| $10.73 | -0.63 | -5.5% | $12.48 | $12.52 | $10.47 | 472,300 | |
| $11.36 | -1.44 | -11.3% | $12.24 | $12.56 | $11.20 | 165,331 | |
| $12.80 | -1.60 | -11.1% | $12.00 | $13.76 | $12.00 | 296,181 | |
| $14.40 | +0.40 | +2.9% | $13.76 | $14.72 | $13.44 | 1,081 | |
| $14.00 | -0.08 | -0.6% | $13.76 | $14.48 | $13.44 | 1,265 | |
| $14.08 | +0.24 | +1.7% | $13.84 | $14.08 | $13.12 | 895 | |
| $13.84 | +0.48 | +3.6% | $13.28 | $13.84 | $12.88 | 900 | |
| $13.36 | -0.24 | -1.8% | $13.20 | $13.84 | $12.80 | 1,144 | |
| $13.60 | 0.00 | 0.0% | $13.68 | $14.40 | $13.44 | 1,586 | |
| $13.60 | 0.00 | 0.0% | $13.76 | $13.84 | $13.12 | 1,238 | |
| $13.60 | -0.32 | -2.3% | $14.08 | $14.24 | $13.04 | 2,413 | |
| $13.92 | -2.48 | -15.1% | $15.92 | $16.16 | $13.60 | 4,555 | |
| $16.40 | +2.40 | +17.1% | $14.40 | $17.12 | $13.44 | 7,431 | |
| $14.00 | +1.60 | +12.9% | $12.00 | $14.96 | $11.68 | 7,361 | |
| $12.40 | -0.24 | -1.9% | $13.60 | $13.60 | $11.60 | 20,524 | |
| $12.64 | +0.08 | +0.6% | $12.64 | $13.12 | $12.08 | 1,052 |
Splits
1 split · NASDAQ:GOSS · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-80 | Consolidation |
- Ticker
- Lang & Schwarz:A2PCBS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 10, 2026
Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update
Latest earnings call · May 18, 2026
Gossamer Bio (NASDAQ:GOSS) Q1 2026 Earnings Call
Replay and transcript
Latest deck · May 18, 2026
Q1 2026 Earnings Presentation
Earnings · 21 slides
Latest news
Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update
Nov 10, 2026
Closed $11.69 (+3.6%) on Nov 11, 2026
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Sep 23, 2026
Closed $10.93 (-0.5%) on Sep 24, 2026
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
Sep 16, 2026
Closed $11.94 (+8.9%) on Sep 17, 2026
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Sep 11, 2026
Closed $10.73 (-5.5%) on Sep 11, 2026
Gossamer Bio Announces 1-for-80 Reverse Stock Split
Sep 9, 2026
Closed $12.80 (-11.1%) on Sep 9, 2026
Gossamer Bio to Present at Cantor Global Healthcare Conference
Sep 4, 2026
Closed $14.00 (-0.6%) on Sep 4, 2026
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
Aug 21, 2026
Closed $12.40 (-1.9%) on Aug 21, 2026
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
Aug 13, 2026
Closed $12.32 (-9.4%) on Aug 14, 2026
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
Jul 27, 2026
Closed $15.92 (+46.3%) on Jul 27, 2026
Gossamer Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 21 in the last 12 months · 110 in all · newest Nov 10, 2026 · oldest 2019
- Calls
- 11 calls with a replay · 11 with a transcript · latest May 18, 2026
- Decks
- 10 decks · latest May 18, 2026
Where Gossamer Bio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:GOSS · Home listing | NASDAQ | United States | USD |
| gettex:4GB | gettex | Germany | EUR |
| LS Exchange:A2PCBS | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2PCBS · This page | Lang & Schwarz | Germany | EUR |
| BOATS:GOSS | BOATS | United States | USD |
| Tradegate:4GB | Tradegate | Germany | EUR |
| Dusseldorf:4GB | Dusseldorf | Germany | EUR |
| Frankfurt:4GB | Frankfurt | Germany | EUR |
| Munich:4GB | Munich | Germany | EUR |
| Stuttgart:4GB | Stuttgart | Germany | EUR |
Valuation
EV/sales 0.7× against a median of 28.6×: 2nd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $55.23M USD
- P/E
- Loss
- EV/sales
- 0.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 99.7%
- Operating margin
- −140.0%
- Net margin
- −159.5%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.56
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Gossamer Bio, Inc. · NASDAQ:GOSS | US$65.57M | US$55.23M | n/a | 0.7× | n/a | n/a | −159.5% | n/a | 1.56 |
| Cingulate Inc. · NASDAQ:CING | US$67.48M | US$1.21B | n/a | n/a | n/a | 3.3× | n/a | 56.0× | 1.41 |
| Energenesis Biomedical Co., Ltd. · TWSE:6657 | US$67.20M | US$47.01M | n/a | 203× | n/a | 3.1× | n/a | 0.0× | n/a |
| MediciNova, Inc. · NASDAQ:MNOV | US$67.11M | US$38.45M | n/a | 41.1× | n/a | 1.6× | n/a | 0.0× | 0.56 |
| Dicot Pharma AB · OMXSTO:DICOT | US$66.64M | US$44.56M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | n/a |
| Cardiff Oncology, Inc. · NASDAQ:CRDF | US$66.34M | US$32.82M | n/a | 58.7× | n/a | 2.4× | n/a | 0.0× | 1.32 |
| Polaryx Therapeutics, Inc. · NASDAQ:PLYX | US$66.30M | US$57.86M | n/a | n/a | n/a | 8.7× | n/a | 0.0× | 1.66 |
| PMV Pharmaceuticals, Inc. · NASDAQ:PMVP | US$66.17M | −US$36.25M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.43 |
| Tenaya Therapeutics, Inc. · NASDAQ:TNYA | US$65.32M | US$1.38M | n/a | 0.5× | n/a | 1.2× | n/a | 0.1× | 2.42 |
| Atara Biotherapeutics, Inc. · NASDAQ:ATRA | US$64.49M | US$64.14M | n/a | 16.2× | n/a | n/a | −368.6% | n/a | 1.43 |
| AlzeCure Pharma AB · OMXSTO:ALZCUR | US$63.92M | US$62.79M | 21.3× | 6.6× | 25.6× | 7.1× | 31.6% | 0.0× | n/a |
| Median of the others | US$66.32M | US$45.79M | 21.3× | 28.6× | 25.6× | 3.0× | −168.5% | 0.0× | 1.43 |
Forecasts
3 strong buy · 1 buy · 3 hold · 1 sell · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 83.40 USD · Analysts' mean
- EPS, year to Dec 2026
- -18.88 · 2 analysts
- Revenue, year to Dec 2026
- 64.61M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Faheem Hasnain | Co-Founder, Chairman, and Chief Executive Officer |
| Bryan Giraudo | Chief Operating Officer & Chief Financial Officer |
| Christian Waage | Executive Vice President, Technical Operations & General Counsel |
| Conor O’Donovan | Senior Vice President, Regulatory Affairs |
| Deanna Weber | Executive Vice President, Human Resources |
| Jean-Marie Bruey | Senior Vice President, Translational Medicine and Research |
| Jeanine Anthony | Senior Vice President, Marketing |
| Kelly Dawson | Senior Vice President, Program Team Lead |
| Lou Cherico | Senior Vice President, Finance & Treasury |
| Rob Roscigno | Senior Vice President of Clinical Development, Pulmonary Vascular Disease |
| Bob Smith | Chief Commercial Officer |
| Caryn Peterson | Chief Development Officer |
Board
| Director | Role |
|---|---|
| Faheem Hasnain | Co-Founder, Chairman, and Chief Executive Officer |
| Greg Ciongoli | Director |
| John Quisel | Director |
| Russell J. Cox | Director |
| Sandra Milligan | Director |
| Skye Drynan | Director |
| Steven D. Nathan | Director |
| Thomas Daniel | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Gossamer Bio (NASDAQ:GOSS) Q1 2026 Earnings Call | Mon, May 18, 2026 · 8:00 AM ET | Replay |
| Gossamer Bio (NASDAQ:GOSS) Q1 2025 Earnings Call | Thu, May 15, 2025 · 4:30 PM ET | Replay |
| Gossamer Bio (NASDAQ:GOSS) Q4 2021 Earnings Call | Thu, Mar 03, 2022 · 4:30 PM ET | Replay |
| Gossamer Bio (NASDAQ:GOSS) Q3 2021 Earnings Call | Mon, Nov 08, 2021 · 4:15 PM ET | Replay |
| Gossamer Bio (NASDAQ:GOSS) Q2 2021 Earnings Call | Mon, Aug 09, 2021 · 4:30 PM ET | Replay |
| Gossamer Bio (NASDAQ:GOSS) Q4 2020 Earnings Call | Thu, Feb 25, 2021 · 8:30 AM ET | Replay |
| Gossamer Bio (NASDAQ:GOSS) Q3 2020 Earnings Call | Tue, Nov 10, 2020 · 4:30 PM ET | Replay |
| Gossamer Bio (NASDAQ:GOSS) Q1 2020 Earnings Call | Fri, Jun 12, 2020 · 4:30 PM ET | Replay |
| Gossamer Bio (NASDAQ:GOSS) Q3 2019 Earnings Call | Tue, Nov 12, 2019 · 4:30 PM ET | Replay |
| Gossamer Bio (NASDAQ:GOSS) Q2 2019 Earnings Call | Thu, Aug 08, 2019 · 4:30 PM ET | Replay |
All 11 calls
| Call | When | Status |
|---|---|---|
| Gossamer Bio (NASDAQ:GOSS) Q1 2019 Earnings Call | Tue, May 14, 2019 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · After close | +3.6% |
| Q2 2026 | Aug 13, 2026 · After close | −9.4% |
| Q1 2026 | May 15, 2026 · After close | −43.2% |
| Q4 2025 | Mar 13, 2026 | −0.9% |
| Q3 2025 | Nov 5, 2025 · After close | −2.5% |
| Q2 2025 | Aug 5, 2025 · After close | −8.3% |
| Q1 2025 | May 15, 2025 · After close | −0.9% |
| Q4 2024 | Mar 3, 2025 · Before open | −4.1% |
| Q3 2024 | Nov 7, 2024 · After close | −0.9% |
| Q2 2024 | Aug 12, 2024 · After close | +3.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · After close | +3.1% |
| Q4 2023 | Mar 5, 2024 · Before open | 0.0% |
| Q3 2023 | Nov 9, 2023 · Before open | −7.6% |
| Q2 2023 | Aug 8, 2023 · After close | −1.6% |
| Q1 2023 | May 9, 2023 · After close | +3.7% |
| Q4 2022 | Mar 17, 2023 · Before open | −8.5% |
| Q3 2022 | Nov 3, 2022 · After close | −0.8% |
| Q2 2022 | Aug 9, 2022 · Before open | −0.4% |
| Q1 2022 | May 10, 2022 · After close | +0.7% |
| Q4 2021 | Mar 3, 2022 · After close | +6.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q1 2026 Earnings Presentation | Earnings | 21 slides | May 18, 2026 |
| Technical Presentation (February 2026) | Technical | 27 slides | Feb 23, 2026 |
| Q1 2025 Earnings Presentation | Earnings | 43 slides | May 15, 2025 |
| Corporate Update (July 2023) | Corporate update | 33 slides | Jul 20, 2023 |
| Technical Presentation (December 2022) | Technical | 39 slides | Dec 6, 2022 |
| ECCO'21 Virtual Congress (June 2021) | Conference | 8 slides | Jun 4, 2021 |
| Technical Presentation (October 2020) | Technical | 23 slides | Oct 13, 2020 |
| Investor Presentation (May 2019) | Investor deck | 38 slides | May 14, 2019 |
| Technical Presentation (2019) | Technical | 12 slides | 2019 |
| Technical Presentation (2019) | Technical | 11 slides | 2019 |
Financings
| Raise | Date |
|---|---|
| Private placement of pre-funded warrants and FDA approval warrants Announced: up to US$250M · US$0.1399 a share · Warrants at US$0.187 · Leerink Partners +1 Dealers: Leerink Partners (co-lead), Cantor (co-lead) Buyers: EcoR1 Capital; 683 Capital Partners, LP; RA Capital Management; Coastlands Capital; Samsara BioCapital; Rock Springs Capital Use of proceeds: Advance clinical development and potential commercialization of seralutinib in PAH and PH-ILD, general corporate purposes and working capital | Aug 21, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Feb 7, 2019.
- Price
- US$16.00 a share
- Shares offered
- 17,250,000 shares of common stock
- Offering size
- US$276 million
- Underwriters' option
- Up to 2,587,500 more shares
- Underwriters
- BofA Merrill Lynch, SVB Leerink, Barclays, Evercore ISI · In the order on the cover
- Shares delivered
- On or about Feb 12, 2019
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Oct 11, 2018 |
| Filed publicly | Dec 21, 2018 |
| Amended twice | Newest Jan 30, 2019 |
| Shares registered with an exchange | Feb 4, 2019 |
| Declared effective by the SEC | Feb 7, 2019 |
| Final prospectus, with the price | Feb 8, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 8, 2019 |
| EFFECT · Notice that a registration is effective | Feb 7, 2019 |
| S-1MEF · Registration of more shares for the same offering | Feb 7, 2019 |
| CORRESP · Letter to the SEC | Feb 5, 2019 |
| CORRESP · Letter to the SEC | Feb 5, 2019 |
| CERT · Exchange's certificate of listing | Feb 5, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 4, 2019 |
| FWP · Free writing prospectus | Jan 30, 2019 |
| S-1/A · Registration statement, amended | Jan 30, 2019 |
| FWP · Free writing prospectus | Jan 24, 2019 |
All 19 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Jan 23, 2019 |
| CORRESP · Letter to the SEC | Dec 26, 2018 |
| CORRESP · Letter to the SEC | Dec 21, 2018 |
| S-1 · Registration statement | Dec 21, 2018 |
| UPLOAD · Letter from the SEC | Dec 14, 2018 |
| DRSLTR · Letter to the SEC with a draft | Nov 29, 2018 |
| DRS/A · Draft registration statement, amended | Nov 29, 2018 |
| UPLOAD · Letter from the SEC | Nov 9, 2018 |
| DRS · Draft registration statement | Oct 11, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 8, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.5M | 114.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 1.00M | 4.15M | 4.38M | 4.43M | 5.17M | 4.27M | 3.09M | 297.0K | 0 | 0 |
| Gross profit | 47.5M | 114.7M | -4.38M | -4.43M | -5.17M | -4.27M | -3.09M | -297.0K | 0 | 0 |
| Research and development | 174.1M | 138.5M | 135.3M | 170.9M | 170.3M | 160.9M | 143.4M | 55.3M | 891.0K | 0 |
| Selling, general and administrative | 37.6M | 36.1M | 38.5M | 47.6M | 45.8M | 49.7M | 39.1M | 44.1M | 262.0K | 83.0K |
| Operating income | -170.7M | -59.9M | -183.8M | -218.6M | -216.1M | -234.0M | -186.1M | -149.0M | -6.65M | -83.0K |
| Depreciation and amortization | 24.0K | 833.0K | 1.61M | 1.83M | 1.74M | 1.41M | 917.0K | 297.0K | 0 | 83.0K |
| EBITDA | -170.7M | -59.1M | -182.2M | -216.8M | -214.4M | -232.6M | -185.2M | -148.7M | -6.65M | 0 |
| Interest expense | 11.0M | 11.5M | 13.5M | 13.9M | 19.4M | 12.7M | 1.94M | 12.0K | 118.0K | 0 |
| Income before tax | -170.5M | -55.6M | -179.8M | -229.4M | -234.0M | -243.4M | -180.3M | -147.0M | 6.77M | -83.0K |
| Income tax | -88.0K | 893.0K | 0 | 0 | 15.1M | 8.22M | 0 | 0 | 0 | -83.0K |
| Net income | -170.4M | -56.5M | -179.8M | -229.4M | -234.0M | -243.4M | -180.3M | -147.0M | -6.77M | -83.0K |
| Earnings per share, basic | -0.75 | -0.25 | -1.18 | -2.71 | -3.13 | -3.55 | -3.29 | -22.59 | -0.74 | -0.72 |
| Earnings per share, diluted | -0.75 | -0.25 | -1.18 | -2.71 | -3.13 | -3.55 | -3.29 | -22.59 | -0.74 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 37.7M | 46.1M | 32.1M | 112.0M | 183.4M | 486.1M | 135.0M | 105.2M | 315.0K | 60.0K |
| Short-term investments | 99.2M | 248.4M | 264.3M | 143.7M | 141.8M | 26.6M | 266.7M | 123.4M | 0 | 0 |
| Receivables | 12.2M | 5.34M | 0 | 200.0K | 200.0K | 1.50M | 500.0K | |||
| Inventory | -136.0K | 365.0K | -1.50M | |||||||
| Current assets | 167.6M | 309.9M | 306.5M | 261.9M | 331.8M | 522.3M | 409.3M | 232.0M | 445.0K | 60.0K |
| Property, plant and equipment | 64.0K | 10.0K | 1.65M | 3.98M | 5.32M | 5.53M | 5.42M | 3.19M | ||
| Total assets | 172.2M | 315.3M | 311.9M | 272.4M | 343.7M | 539.4M | 426.6M | 239.4M | 445.0K | 60.0K |
| Accounts payable | 5.96M | 2.32M | 5.53M | 1.46M | 3.24M | 7.51M | 956.0K | 2.18M | 97.0K | 40.0K |
| Current liabilities | 63.4M | 45.0M | 51.6M | 49.2M | 39.9M | 38.6M | 36.9M | 20.4M | 1.27M | 143.0K |
| Long-term debt | 198.5M | 0 | 814.0K | 12.0M | 29.1M | 28.7M | 28.5M | 6.04M | 40.0K | |
| Total debt | 202.9M | 0 | 12.4M | 23.6M | 29.1M | 28.7M | 28.5M | 6.04M | 40.0K | |
| Total liabilities | 295.0M | 285.8M | 249.1M | 260.4M | 222.2M | 218.7M | 74.1M | 21.1M | 7.31M | 183.0K |
| Shareholders' equity | -122.8M | 29.5M | 62.8M | 12.1M | 121.5M | 320.7M | 352.5M | -120.1M | -6.86M | -123.0K |
| Shares outstanding | 2.92M | 226.6M | 225.4M | 94.4M | 75.8M | 73.9M | 61.6M | 8.05M | 75.5M | 114.5K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -171.3M | -3.47M | -159.2M | -187.0M | -188.9M | -176.4M | -144.8M | -51.0M | -5.75M | 20.0K |
| Capital spending | -79.0K | 0 | 0 | -410.0K | -1.55M | -1.50M | -2.97M | -3.49M | -3.49M | -3.49M |
| Free cash flow | -171.3M | -3.47M | -159.2M | -187.4M | -190.4M | -177.9M | -147.8M | -54.5M | -5.75M | 20.0K |
| Cash from investing | 156.4M | 29.0M | -111.0M | -1.03M | -117.4M | 215.3M | -147.1M | -144.7M | -144.7M | -144.7M |
| Cash from financing | 6.42M | -11.5M | 190.2M | 117.1M | 3.33M | 312.5M | 321.6M | 300.9M | 6.00M | 40.0K |
| Share buybacks | 629.0K | 444.0K | 122.9M | 3.33M | 117.6M | 293.4M | 303.0M | |||
| Change in cash | -8.34M | 14.0M | -79.9M | -71.5M | -303.2M | 351.5M | 29.7M | 105.1M | 255.0K | 0 |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-3 · Registration statement | Nov 16, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 28, 2026 | Meeting outcome | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 8, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 28, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 28, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 23, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 22, 2026 | Insider trade | SEC |
| DEF 14A · Proxy statement | Sep 16, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 16, 2026 | Management or board change | SEC |
| 8-K · Current report | Sep 11, 2026 | Current report | SEC |
| 8-K · Current report | Sep 9, 2026 | Current report | SEC |
| D | Sep 4, 2026 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Sep 3, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 3, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 26, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 24, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 21, 2026 | Material contract | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 27, 2026 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 24, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 14, 2026 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 1, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 1, 2026 | Current report | SEC |
| 8-K · Current report | Jun 17, 2026 | Current report | SEC |
| SCHEDULE 13D · Big-stake notice | Jun 11, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 11, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 11, 2026 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Jun 9, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 9, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 4, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 4, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 2, 2026 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | May 18, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | May 18, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 18, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 9, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 24, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Mar 19, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Mar 17, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 17, 2026 | Results | SEC |
| 10-K · Annual report | Mar 17, 2026 | Annual report | SEC |
| POSASR | Mar 17, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 2, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 24, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 23, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| S-3ASR · Registration statement | Jan 28, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 25, 2025 | Financing | SEC |
| 4 · Change in ownership | Aug 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 25, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 16, 2025 | Current report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 13, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 13, 2025 | Results | SEC |
| 10-K · Annual report | Mar 13, 2025 | Annual report | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 19, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2025 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Sep 13, 2024 | Current report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Aug 2, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jul 18, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 8-K · Current report | May 24, 2024 | Current report | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2024 | Material contract | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 12, 2024 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 5, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2024 | Results | SEC |
| 8-K · Current report | Mar 4, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jan 11, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 11, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 29, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 29, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 29, 2023 | Management or board change | SEC |
| 8-K · Current report | Nov 27, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 8-K · Current report | Oct 20, 2023 | Current report | SEC |
| 8-K · Current report | Sep 7, 2023 | Management or board change | SEC |
This page holds 200 of 490 filings. Open Filings
Cap table
Built by 6ix from Gossamer Bio, Inc.’s releases · as of Nov 7, 2026
- Common shares
- 6,116,390
- Fully diluted
- 6,116,390
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 6,116,390 | Nov 7, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 7, 2026 | 6,116,390 |
| Sep 11, 2026 | |
| Sep 9, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Faheem Hasnain Other companies: Aspen Neuroscience, Inc. (Aspen Executive Chairman · Since at least Nov 2, 2026); Kura Oncology, Inc. (Lead Independent Director · Since at least Apr 23, 2015); Nuvation Bio Inc. (Director · Jun 30, 2020 – Feb 10, 2021 · Past); Tocagen Inc (Director · Apr 12, 2017 – Oct 4, 2019 · Past); Immunic, Inc. (Director · Aug 11, 2016 – Sep 13, 2018 · Past); Ambit Biosciences Corp (Director · May 15, 2013 – Nov 10, 2014 · Past); Receptos Inc (President & CEO, Director · May 8, 2013 – Aug 25, 2015 · Past); Somaxon Pharmaceuticals Inc (Director · Sep 16, 2010 – Dec 31, 2012 · Past); Facet Biotech Corp (President & CEO, Director · Dec 9, 2008 – Apr 21, 2010 · Past); PDL BioPharma Inc (President & CEO, Director · Oct 1, 2008 – Oct 1, 2008 · Past) | Co-Founder, Chairman, and Chief Executive Officer · Since at least Feb 7, 2019 |
| Kristina Burow Other companies: Kardigan, Inc. (Director · Since at least Jun 22, 2026); Metsera, Inc. (Director · Since at least Jan 30, 2025); Boundless Bio, Inc. (Director · Since at least Mar 27, 2024); Neumora Therapeutics, Inc. (Director · Since at least Sep 14, 2023); Scholar Rock Holding Corporation (Director · Since at least May 23, 2018); Metacrine Inc (Director · Sep 15, 2020 – May 24, 2021 · Past); Beam Therapeutics Inc. (Director · Feb 5, 2020 – Jun 6, 2023 · Past); Vir Biotechnology, Inc. (Director · Oct 10, 2019 – May 21, 2020 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 24, 2021 · Past); Receptos Inc (Director · Aug 25, 2015 – Aug 25, 2015 · Past) | Director · Feb 7, 2019 – Jun 8, 2023 · Past |
| Sheila Gujrathi Other companies: Bolt Biotherapeutics, Inc. (Chief Strategy Officer · Since at least Oct 23, 2026); BlossomHill Therapeutics, Inc. (Director · Since at least Aug 6, 2026); Processa Pharmaceuticals, Inc. (Director · Since at least Jul 28, 2026); Ventyx Biosciences Inc (Director · Since at least Oct 20, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Jun 15, 2020 · Past); Five Prime Therapeutics Inc (Director · Dec 2, 2015 – May 10, 2018 · Past); Receptos Inc (Chief Medical Officer · May 8, 2013 – Aug 25, 2015 · Past) | President & CEO, Director · Feb 7, 2019 – Feb 14, 2020 · Past |
| Otello Stampacchia Other companies: Windward Bio Group AG (Founder & Managing Director, Omega Fund Management, LLC · Since at least Nov 16, 2026); ImageneBio, Inc. (Director · Since at least Mar 25, 2021); Omega Alpha SPAC (Chief Executive Officer, Director · Jan 6, 2021 – Jan 11, 2021 · Past); Kronos Bio Inc (Director · Oct 8, 2020 – Jun 22, 2022 · Past); Morphic Holding Inc (Director · Jun 26, 2019 – Apr 29, 2021 · Past); Replimune Group, Inc. (Director · Jul 19, 2018 – Nov 19, 2021 · Past) | Director · Feb 7, 2019 – Sep 10, 2019 · Past |
| Jakob Dupont Other companies: Bolt Biotherapeutics, Inc. (Director · Since at least Sep 3, 2024); Pyxis Oncology, Inc. (Director · Since at least Aug 23, 2023); Apexigen Inc. (Director · Jul 29, 2022 – Aug 23, 2023 · Past); Atara Biotherapeutics, Inc. (EVP, Head of R&D · May 14, 2020 – Mar 2, 2023 · Past); OncoMed Pharmaceuticals Inc (SVP & Chief Medical Officer · Jul 17, 2013 – Oct 9, 2016 · Past) | Chief Medical Officer · Feb 7, 2019 – Feb 14, 2020 · Past |
| Thomas Daniel Other companies: Dianthus Therapeutics, Inc. (Director · Jun 20, 2018 – Jun 28, 2022 · Past); Larimar Therapeutics, Inc. (Director · Mar 3, 2016 – May 12, 2021 · Past); Juno Therapeutics Inc (Director · Aug 11, 2015 – Mar 5, 2018 · Past); Epizyme Inc (Director · May 30, 2013 – May 30, 2013 · Past); Celgene Corporation (see remarks · Feb 15, 2012 – Dec 31, 2015 · Past) | Director · Since at least Feb 7, 2019 |
| Greg Ciongoli Other companies: Theravance Biopharma, Inc. (Director · Since at least Nov 4, 2026); Regenxbio Inc. (Independent Board Member · Since at least Aug 25, 2026); Zymeworks Inc. (Director · Since at least Jan 12, 2026); Atara Biotherapeutics, Inc. (Director · Since at least Sep 3, 2025) | Director · Since at least Sep 16, 2026 |
| Renée Galá Other companies: DexCom, Inc. (Director · Since at least Mar 6, 2025); Jazz Pharmaceuticals plc (President & CEO, Director · Since at least Mar 16, 2020); Corcept Therapeutics Incorporated (Director · Mar 6, 2018 – Aug 20, 2018 · Past); Theravance Biopharma, Inc. (SVP, Chief Financial Officer · Nov 20, 2017 – Nov 20, 2018 · Past) | Director · Feb 7, 2019 – Jun 8, 2023 · Past |
| Gregory Austin Ciongoli Other companies: Regenxbio Inc. (Director · Since at least Aug 25, 2026); Zymeworks Inc. (Director · Since at least Aug 10, 2025); Atara Biotherapeutics, Inc. (Director · Since at least Sep 3, 2024) | Director · Since at least Sep 16, 2026 |
| Russell J. Cox Other companies: Immunic, Inc. (Chief Executive Officer, Director · Jan 3, 2018 – Jan 11, 2019 · Past); Spyre Therapeutics, Inc. (Director · Apr 6, 2016 – Jun 22, 2023 · Past); Jazz Pharmaceuticals plc (EVP & COO · Feb 8, 2011 – Dec 11, 2017 · Past) | Director · Since at least Feb 7, 2019 |
All 31 people
| Person | Seat |
|---|---|
| Sandra Milligan Other companies: Spyre Therapeutics, Inc. (Chair of the Nominating and Corporate Governance Committee · Since at least May 14, 2024); Aspira Women's Health Inc. (Interim CEO & President · Apr 1, 2024 – Dec 31, 2024 · Past); Organon & Co. (Head of Research & Development · Jun 2, 2021 – May 4, 2023 · Past) | Director · Since at least Jun 10, 2021 |
| John Quisel Other companies: Disc Medicine, Inc. (Chief Executive Officer · Since at least Dec 29, 2022); Acceleron Pharma Inc (EVP, Chief Business Officer · Sep 18, 2013 – Jan 2, 2020 · Past) | Director · Since at least Nov 28, 2023 |
| Bryan Giraudo Other companies: Protagonist Therapeutics, Inc. (Director · Since at least May 15, 2018) | Chief Operating Officer & Chief Financial Officer · Since at least Feb 7, 2019 |
| Caryn Peterson Other companies: Aspen Neuroscience, Inc. (Chief Development Officer, Gossamer · Since at least Nov 5, 2026) | Chief Development Officer · Since at least Apr 16, 2021 |
| Christian Waage Other companies: Heron Therapeutics, Inc. (Director · Since at least Nov 5, 2026) | Executive Vice President, Technical Operations & General Counsel · Since at least Nov 5, 2026 |
| Luisa Salter-Cid Other companies: Jounce Therapeutics Inc (Director · Feb 10, 2021 – May 3, 2023 · Past) | Chief Scientific Officer · Feb 7, 2019 – Mar 23, 2021 · Past |
| Waage Christian Other companies: Heron Therapeutics, Inc. (Director · Since at least Jan 19, 2024) | EVP, Tech Ops and Admin · Since at least Nov 20, 2023 |
| Bob Smith | Chief Commercial Officer · Since at least Nov 4, 2026 |
| Conor O’Donovan | Senior Vice President, Regulatory Affairs · Since at least Nov 5, 2026 |
| Deanna Weber | Executive Vice President, Human Resources · Since at least Nov 5, 2026 |
| Jeanine Anthony | Senior Vice President, Marketing · Since at least Nov 5, 2026 |
| Jean-Marie Bruey | Senior Vice President, Translational Medicine and Research · Since at least Nov 5, 2026 |
| Kelly Dawson | Senior Vice President, Program Team Lead · Since at least Nov 5, 2026 |
| Laura Carter | Chief Scientific Officer · May 4, 2022 – Mar 20, 2023 · Past |
| Lou Cherico | Senior Vice President, Finance & Treasury · Since at least Nov 5, 2026 |
| Richard Aranda | Chief Medical Officer · Since at least Jun 21, 2021 |
| Robert Paul Smith Jr | Chief Commercial Officer · Since at least Dec 4, 2023 |
| Rob Roscigno | Senior Vice President of Clinical Development, Pulmonary Vascular Disease · Since at least Nov 5, 2026 |
| Skye Drynan | Director · Since at least Mar 11, 2024 |
| Steven D Nathan | Director · Since at least Mar 11, 2024 |
| Steven D. Nathan | Director · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Gossamer Bio, Inc.